Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Robert W. Duggan as Executive Chairman Oxford, UK, and Cambridge, MA, US, 26 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces it has appointed Robert W. Duggan as Executive Chairman of the Board of Directors with immediate effect. Glyn Edwards will continue as an...
Author: @admin
Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
DUBLIN, Ireland and CHICAGO, Feb. 19, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced its participation at the 9th Annual...
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company Continues Operations with No Anticipated Disruption to Product Supply or Support MORRISTOWN, N.J., Feb. 13, 2020 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (the...
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures
Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company Continues Operations with No Anticipated Disruption to Product Supply or Support MORRISTOWN, N.J., Feb. 13, 2020 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (the...
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
JERSEY CITY, N.J., Feb. 13, 2020 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis...
AIM Delisting Reminder
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 – Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”)...
AIM Delisting Reminder
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 – Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”)...
AIM Delisting Reminder
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 – Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”)...
Director/PDMR Shareholding
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) READ FULL TEXT
Director/PDMR Shareholding
Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) READ FULL TEXT